Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for (Study ST000684)

(Analysis AN001054)

Metabolite	Structure	F1	F2	F3	F4	F5	F6	F7	F8	F9	F10
PC 40:0; [M-Ac-H]-@8.62	ME190613	3.19	0.38	0.44	0.92	0.16	2.99	0.27	0.26	0.96	0.45
PC 42:1; [M-Ac-H]-@8.63	ME190620	3.12	0.14	0.35	0.80	0.48	3.16	0.11	0.22	1.13	0.49
PC 42:2; [M-Ac-H]-@8.23	ME190622	2.61	0.47	0.40	1.25	0.54	2.48	0.27	0.26	1.20	0.53
PC 40:1; [M-Ac-H]-@8.18	ME190614	2.83	0.44	0.38	0.67	0.66	2.35	0.52	0.43	0.94	0.78
PC 46:5; [M-Ac-H]-@8.35	ME190627	2.78	0.47	0.46	0.95	0.45	1.94	0.64	0.63	1.24	0.44
PC 28:1; [M-Ac-H]-@4.59	ME190579	2.14	1.03	0.31	0.57	0.42	2.68	1.25	0.36	0.76	0.48
PG 30:0; [M-H]-@5.17	ME190648	3.03	0.62	0.73	0.18	0.35	2.82	0.76	0.80	0.36	0.36
PC 26:0; [M-Ac-H]-@4.43	ME190577	3.73	0.24	0.17	0.25	0.26	3.91	0.11	0.84	0.37	0.11
PC 42:0; [M-Ac-H]-@9.05	ME190619	5.13	0.10	0.07	0.34	0.04	3.66	0.09	0.12	0.39	0.07
PC 38:4; [M-Ac-H]-@6.67	ME190609	1.22	0.60	0.43	2.32	0.23	1.25	0.49	0.36	2.80	0.29
PC 42:6; [M-Ac-H]-@6.83	ME190625	1.24	0.57	0.34	1.95	0.39	1.37	0.56	0.32	2.76	0.48
PC 42:9; [M-Ac-H]-@5.86	ME190626	1.45	0.44	0.47	2.01	0.42	1.11	0.33	0.42	2.39	0.98
PC 34:4; [M-Ac-H]-@5.50	ME190592	1.45	0.56	0.41	2.09	0.33	1.33	0.57	0.42	2.38	0.46
PC 42:5; [M-Ac-H]-@7.16	ME190624	1.76	0.57	0.33	1.92	0.37	1.27	0.54	0.40	2.34	0.50
PC 37:3; [M-Ac-H]-@6.63	ME190604	1.32	0.80	0.48	1.92	0.37	1.29	0.68	0.36	2.20	0.57
PG 42:6; [M-H]-@5.80	ME190683	1.21	0.90	0.58	1.72	0.47	1.21	0.66	0.56	2.08	0.61
PG 42:11; [M-H]-@4.25	ME190682	0.22	0.83	0.44	3.16	0.24	0.22	0.55	0.24	3.59	0.50
PG 44:10; [M-H]-@5.12	ME190686	0.72	0.66	0.46	3.73	0.32	0.52	0.46	0.29	2.56	0.28
PG 44:11; [M-H]-@4.78	ME190687	0.58	0.50	0.32	3.73	0.26	0.58	0.37	0.19	3.19	0.29
PG 44:12; [M-H]-@4.55	ME190688	0.65	0.53	0.38	3.54	0.26	0.66	0.33	0.21	3.07	0.37
PC 34:5; [M-Ac-H]-@5.05	ME190593	1.12	0.62	0.51	2.55	0.29	0.99	1.29	0.53	1.83	0.28
PG 40:9; [M-H]-@4.33	ME190680	0.32	1.08	0.40	2.97	0.24	0.37	1.42	0.33	2.56	0.31
PG 40:8; [M-H]-@4.68	ME190679	0.81	1.25	0.43	2.67	0.29	0.81	0.93	0.26	2.20	0.35
PG 44:9; [M-H]-@5.34	ME190690	0.75	1.06	0.52	2.78	0.31	0.57	0.88	0.38	2.35	0.41
PG 42:8; [M-H]-@5.23	ME190684	1.11	0.90	0.26	2.94	0.14	0.94	0.64	0.16	2.70	0.20
PG 42:10; [M-H]-@4.60	ME190681	0.78	0.93	0.32	3.27	0.18	0.68	0.73	0.16	2.72	0.22
PG 42:9; [M-H]-@4.87	ME190685	0.84	0.99	0.28	3.23	0.18	0.74	0.66	0.22	2.66	0.21
PI 36:2; [M-H]-@5.85	ME190694	0.47	0.22	0.93	0.25	2.81	0.41	0.29	0.95	0.24	3.43
FFA(18:1)	ME190559	0.06	0.36	1.55	0.11	2.76	0.08	0.44	1.62	0.14	2.87
CL 74:1; [M-2H](2-)@6.66	ME190552	0.20	0.44	1.14	0.19	2.96	0.28	0.46	1.18	0.19	2.96
PG 36:2; [M-H]-@5.86	ME190662	0.12	0.41	1.29	0.07	2.98	0.16	0.50	1.35	0.10	3.03
PS 36:5; [M-H]-@4.98	ME190711	0.14	0.65	1.77	0.24	2.26	0.30	1.13	1.33	0.25	1.93
CL 74:7; [M-2H](2-)@6.04	ME190555	0.74	0.52	0.79	0.19	2.64	0.61	0.45	1.18	0.20	2.67
PS 35:1; [M-H]-@6.19	ME190707	0.62	0.63	0.76	0.26	2.88	0.47	0.49	0.92	0.29	2.69
PS 36:4; [M-H]-@5.40	ME190710	0.24	0.71	1.27	0.19	2.79	0.28	0.74	1.46	0.20	2.13
FFA(18:2)	ME190560	0.22	0.60	1.38	0.45	2.06	0.30	0.63	1.26	0.50	2.60
PS 38:6; [M-H]-@5.28	ME190716	0.33	0.86	1.25	0.24	2.29	0.47	0.69	1.21	0.42	2.24
N-(hexadecanoyl)-sphing-4-enine; [M-H]-@6.77	ME190573	0.46	0.76	1.11	0.46	2.16	0.50	0.83	1.13	0.44	2.17
PS 34:1; [M-H]-@5.89	ME190705	0.48	0.86	1.02	0.43	2.01	0.49	0.79	1.15	0.51	2.28
CL 74:3; [M-2H](2-)@6.20	ME190553	0.43	0.71	0.93	0.31	2.45	0.46	0.73	1.11	0.50	2.37
plasmenyl-PE 42:4; [M-H]-@8.00	ME190740	0.48	0.51	0.96	0.52	2.33	0.52	0.62	1.08	0.50	2.47
PC 34:1; [M-Ac-H]-@6.55	ME190589	0.30	0.54	1.16	0.33	2.48	0.37	0.58	1.24	0.41	2.59
PG 34:1; [M-H]-@5.79	ME190655	0.54	0.44	1.09	0.25	2.49	0.56	0.50	1.38	0.28	2.48
PG 32:0; [M-H]-@5.77	ME190650	1.90	0.91	1.06	0.40	0.67	1.78	0.97	1.29	0.27	0.74
PG 36:4; [M-H]-@5.48	ME190664	1.63	0.61	0.90	0.40	1.44	1.30	0.60	1.54	0.51	1.06
CL 72:6; [M-2H](2-)@9.32	ME190550	1.17	0.22	0.68	1.17	1.22	1.16	0.55	0.73	1.47	1.64
PC 40:7; [M-Ac-H]-@6.18	ME190618	0.83	0.63	0.63	1.32	1.15	1.04	0.38	0.52	1.72	1.78
PC 35:3; [M-Ac-H]-@6.03	ME190596	0.87	0.76	0.67	1.30	0.93	1.22	0.58	0.57	1.87	1.24
PC 36:3; [M-Ac-H]-@6.30	ME190599	0.94	0.75	0.65	1.31	0.95	1.25	0.51	0.60	1.66	1.37
PI 38:3; [M-H]-@6.19	ME190696	1.08	0.63	0.80	1.77	0.75	0.79	0.60	0.95	1.56	1.07
PI 38:4; [M-H]-@5.90	ME190697	0.69	0.71	0.98	1.82	0.75	0.55	0.56	0.74	2.06	1.14
PC 36:6; [M-Ac-H]-@5.32	ME190602	0.91	0.94	0.73	1.53	1.09	1.18	0.81	0.90	1.39	0.51
plasmenyl-PE 38:5; [M-H]-@6.70	ME190735	0.84	1.08	0.80	1.18	0.91	0.94	0.86	0.80	1.48	1.10
plasmenyl-PE 42:5; [M-H]-@7.80	ME190741	1.03	0.94	0.70	1.10	0.96	1.03	0.77	0.75	1.56	1.15
PC 40:4; [M-Ac-H]-@7.11	ME190615	1.33	0.82	0.68	1.30	0.76	1.31	0.91	0.56	1.52	0.80
PC 42:10; [M-Ac-H]-@5.65	ME190621	1.42	0.66	0.73	1.39	0.82	1.26	0.60	0.57	1.61	0.95
PI 40:5; [M-H]-@5.97	ME190700	1.40	0.74	0.81	1.36	0.77	1.19	0.65	0.62	1.51	0.94
PG 36:0; [M-H]-@6.92	ME190660	1.14	0.61	0.77	1.28	0.86	1.10	0.81	0.85	1.62	0.97
PC 35:4; [M-Ac-H]-@5.86	ME190597	1.32	0.87	0.80	1.27	0.73	0.98	0.77	0.78	1.61	0.87
PS 38:4; [M-H]-@5.93	ME190714	1.13	0.92	0.82	1.30	0.69	1.11	0.87	0.75	1.50	0.91
PC 37:4; [M-Ac-H]-@6.40	ME190605	1.22	0.89	0.71	1.32	0.87	0.96	0.65	0.80	1.43	1.14
PE 36:0; [M-H]-@7.76	ME190634	1.26	0.84	0.77	1.18	0.87	1.20	0.65	0.79	1.46	0.97
PE 39:6; [M-H]-@6.54	ME190642	1.20	1.11	0.68	1.13	0.65	1.02	1.01	0.60	1.67	0.93
PS 40:6; [M-H]-@5.86	ME190719	1.26	1.03	0.69	1.09	0.64	1.40	0.83	0.71	1.38	0.97
PC 40:6; [M-Ac-H]-@6.55	ME190617	1.07	0.51	0.57	1.87	0.75	1.16	0.47	0.48	2.09	1.03
PG 44:8; [M-H]-@5.71	ME190689	1.19	0.71	0.60	1.86	0.97	0.99	0.63	0.48	1.78	0.78
PC 38:3; [M-Ac-H]-@6.97	ME190608	1.04	0.72	0.73	1.71	0.69	1.26	0.71	0.48	1.67	1.00
PC 40:5; [M-Ac-H]-@6.78	ME190616	1.05	0.81	0.57	1.53	0.90	1.18	0.74	0.63	1.82	0.78
PG 36:1; [M-H]-@6.50	ME190661	1.12	0.91	0.71	1.40	0.61	0.93	0.78	0.66	2.17	0.73
PC 39:4; [M-Ac-H]-@7.09	ME190612	0.80	1.26	0.62	1.63	0.66	1.09	0.80	0.59	1.78	0.78
PS 38:3; [M-H]-@6.30	ME190713	1.22	0.99	0.63	1.58	0.51	1.34	0.75	0.66	1.49	0.81
PC 35:1; [M-Ac-H]-@6.86	ME190594	1.06	1.11	0.69	1.44	0.46	1.33	0.93	0.64	1.70	0.65
PC 37:2; [M-Ac-H]-@7.03	ME190603	1.13	1.15	0.68	1.46	0.50	1.18	0.80	0.54	1.99	0.57
PC 29:0; [M-Ac-H]-@5.48	ME190580	0.93	1.14	0.91	0.93	0.87	1.07	1.48	0.87	0.94	0.86
PC 31:0; [M-Ac-H]-@6.19	ME190584	0.62	1.44	1.08	0.69	0.93	0.67	1.63	1.08	0.89	0.96
PC 33:0; [M-Ac-H]-@6.70	ME190587	0.85	1.27	1.02	0.94	0.71	0.85	1.50	0.86	1.01	0.98
PG 38:6; [M-H]-@4.82	ME190672	0.72	1.50	1.12	0.87	0.84	0.72	1.49	0.86	0.93	0.96
PC 34:3; [M-Ac-H]-@5.68	ME190591	1.03	1.42	0.80	0.77	0.81	1.19	1.12	0.76	0.89	1.21
PC 33:1; [M-Ac-H]-@6.30	ME190588	1.01	1.58	0.72	0.69	0.85	1.02	1.26	1.22	0.76	0.89
PI 34:2; [M-H]-@5.27	ME190692	1.03	1.48	0.89	0.68	0.96	0.99	1.48	0.90	0.73	0.86
PE 42:4; [M-H]-@7.74	ME190647	1.22	1.07	0.81	0.69	1.04	1.16	1.02	0.88	0.91	1.19
PG 38:4; [M-H]-@5.51	ME190670	1.19	1.13	0.75	0.77	1.36	1.06	0.77	0.92	0.64	1.41
PS 40:7; [M-H]-@5.40	ME190720	1.08	1.13	0.85	0.76	1.26	1.02	0.99	0.97	0.66	1.29
plasmenyl-PE 34:3; [M-H]-@6.45	ME190730	1.16	1.13	0.99	1.08	0.77	1.06	0.74	1.04	0.99	1.04
N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.40	ME190575	0.91	1.42	0.92	0.99	0.97	1.00	0.72	0.77	1.15	1.13
PG 38:5; [M-H]-@5.17	ME190671	0.80	1.44	0.97	1.03	0.90	0.82	1.02	0.80	1.21	1.01
PE 35:1; [M-H]-@7.06	ME190633	0.74	1.36	0.96	0.64	1.04	0.82	1.21	1.08	0.88	1.27
FFA(22:2)	ME190567	0.70	0.98	1.29	0.97	0.96	0.78	0.83	0.95	1.18	1.36
PG 40:5; [M-H]-@5.65	ME190676	0.69	1.10	1.07	0.89	1.23	0.69	1.02	0.91	1.10	1.31
PE 40:6; [M-H]-@6.77	ME190645	0.87	0.97	0.98	0.88	1.21	0.97	1.02	0.89	0.97	1.25
PS 40:4; [M-H]-@6.44	ME190717	0.92	0.96	1.07	0.84	1.13	0.90	1.09	1.07	0.90	1.13
PC 30:0; [M-Ac-H]-@5.83	ME190582	1.03	1.02	0.93	0.83	0.80	1.17	1.15	0.95	0.99	1.12
PS 40:5; [M-H]-@6.04	ME190718	0.99	0.87	1.01	0.88	0.90	1.00	1.16	0.99	0.96	1.24
PE 37:1; [M-H]-@7.58	ME190637	0.90	1.15	0.88	0.82	0.80	0.93	0.87	1.02	1.23	1.41
PS 38:2; [M-H]-@6.56	ME190712	0.89	1.08	1.14	0.79	0.89	1.17	0.86	0.81	0.99	1.38
PC 28:0; [M-Ac-H]-@5.13	ME190578	1.63	1.04	0.57	1.08	0.34	1.95	0.97	0.65	1.20	0.57
CerP 34:1; [M-H]-@5.75	ME190556	1.33	0.94	0.66	1.13	0.95	1.30	0.96	0.98	1.07	0.68
PE 35:0; [M-H]-@7.41	ME190632	1.17	0.87	0.68	1.00	1.17	1.10	1.09	1.02	1.00	0.89
PI 40:4; [M-H]-@6.35	ME190699	1.62	0.97	0.86	0.89	0.57	1.23	1.11	0.88	0.92	0.95
PI 40:6; [M-H]-@5.65	ME190701	1.65	1.05	0.74	1.07	0.54	1.47	0.92	0.67	1.14	0.75
N-(tetracosanoyl)-sphing-4-enine; [M-H]-@8.88	ME190576	1.57	0.79	0.69	1.00	0.84	1.40	0.76	0.80	1.10	1.05
PE 38:2; [M-H]-@7.43	ME190640	1.29	1.01	0.79	0.81	0.71	1.42	0.73	0.81	1.02	1.41
N-(hexadecanoyl)-sphinganine; [M-H]-@7.04	ME190574	0.88	0.70	0.79	0.72	2.27	0.81	0.60	0.74	0.67	1.81
PI 36:1; [M-H]-@6.35	ME190693	1.27	0.42	0.79	0.34	1.88	1.20	0.39	0.86	0.50	2.38
plasmenyl-PE 40:2; [M-H]-@8.18	ME190737	1.42	0.84	0.48	0.67	0.85	1.67	0.55	0.49	1.36	1.66
plasmenyl-PE 38:1; [M-H]-@8.11	ME190733	1.17	0.80	0.55	0.63	1.16	1.72	0.61	0.57	0.95	1.83
plasmenyl-PE 40:1; [M-H]-@8.55	ME190736	1.15	0.67	0.65	0.66	1.34	1.32	0.64	0.71	0.91	1.95
FFA(24:3)	ME190572	0.35	0.75	1.30	1.16	1.27	0.37	0.83	1.20	1.18	1.58
FFA(22:3)	ME190568	0.40	0.86	1.02	1.16	1.08	0.47	0.62	0.91	1.54	1.95
FFA(24:1)	ME190570	0.60	0.79	0.88	1.44	1.07	0.60	0.58	0.81	1.67	1.56
FFA(24:2)	ME190571	0.58	0.81	1.10	1.30	1.06	0.53	0.61	0.95	1.42	1.64
CL 72:7; [M-2H](2-)@9.16	ME190551	1.03	0.37	0.78	0.91	1.29	1.13	0.44	1.01	0.75	2.29
PC 38:6; [M-Ac-H]-@5.94	ME190611	0.86	0.40	0.86	0.95	1.47	1.03	0.59	0.83	0.94	2.06
PS 36:2; [M-H]-@5.91	ME190709	0.89	0.64	0.87	0.71	1.56	1.09	0.59	0.81	0.85	1.99
lysoPE 22:6; [M-H]-@1.23	ME190725	0.65	0.79	0.76	0.83	1.27	0.80	0.61	0.77	1.47	2.05
PE 42:1; [M-H]-@8.78	ME190646	0.93	0.78	0.80	0.89	1.23	0.83	0.81	0.76	1.13	1.84
PC 38:5; [M-Ac-H]-@6.23	ME190610	0.58	0.62	0.89	1.11	1.58	0.72	0.67	0.90	1.20	1.73
CL 72:3; [M-2H](2-)@6.19	ME190549	0.73	0.58	0.92	1.04	1.46	0.67	0.66	1.20	1.22	1.51
PC 36:4; [M-Ac-H]-@6.09	ME190600	0.78	0.63	1.05	0.93	1.36	0.82	0.73	1.00	1.02	1.67
PC 37:6; [M-Ac-H]-@5.72	ME190606	0.69	1.03	0.99	1.00	1.27	0.70	0.66	0.92	1.10	1.65
PG 40:7; [M-H]-@5.06	ME190678	0.64	0.82	1.01	1.13	1.33	0.72	0.54	0.72	1.41	1.68
PC 42:4; [M-Ac-H]-@7.58	ME190623	0.83	0.74	0.89	0.68	1.73	1.09	0.66	1.02	0.87	1.47
PC 36:1; [M-Ac-H]-@7.16	ME190598	0.96	0.62	0.98	0.89	1.17	1.16	0.69	0.97	1.04	1.53
PC 38:2; [M-Ac-H]-@7.30	ME190607	1.01	0.72	0.85	1.02	1.18	1.22	0.74	0.75	1.07	1.43
lysoPE 16:1; [M-H]-@1.18	ME190723	0.21	1.82	1.21	0.22	1.67	0.41	1.21	1.53	0.47	1.26
lysoPE 17:1; [M-H]-@1.51	ME190724	0.33	1.34	1.58	0.36	1.78	0.45	1.36	1.12	0.53	1.13
CL 74:5; [M-2H](2-)@6.74	ME190554	1.06	1.10	1.22	0.68	1.24	0.98	0.71	1.22	0.34	1.47
plasmenyl-PE 32:0; [M-H]-@7.00	ME190726	0.91	0.89	1.25	0.47	1.06	0.99	1.04	1.55	0.50	1.34
PG 39:6; [M-H]-@5.00	ME190674	0.53	0.96	1.08	0.45	1.35	0.51	1.66	1.11	0.89	1.46
PG 38:3; [M-H]-@5.82	ME190669	0.57	1.09	1.23	0.55	1.28	0.68	1.18	1.01	0.65	1.76
PE 37:4; [M-H]-@6.60	ME190638	0.66	1.04	1.14	0.56	1.44	0.73	1.18	1.23	0.63	1.37
PE 39:4; [M-H]-@7.01	ME190641	0.70	1.19	1.03	0.64	1.40	0.58	1.32	1.00	0.72	1.41
PE 30:0; [M-H]-@6.01	ME190628	0.49	1.34	0.93	0.49	1.24	0.57	1.54	1.21	0.52	1.66
PS 32:0; [M-H]-@5.81	ME190703	0.50	1.30	1.16	0.58	1.10	0.57	1.55	1.34	0.66	1.26
PC 34:2; [M-Ac-H]-@6.10	ME190590	0.59	1.20	1.23	0.48	1.11	0.78	1.34	1.20	0.59	1.48
PS 34:2; [M-H]-@5.38	ME190706	0.75	1.41	1.28	0.44	1.23	0.56	1.34	1.22	0.42	1.34
PE 40:0; [M-H]-@8.67	ME190643	0.54	0.90	0.73	0.88	1.77	0.48	1.03	1.04	0.77	1.87
PE 40:5; [M-H]-@7.00	ME190644	0.75	0.96	1.02	0.65	1.34	0.86	1.10	1.08	0.75	1.49
PI 34:1; [M-H]-@5.72	ME190691	0.91	0.79	0.99	0.75	1.28	0.97	0.97	1.01	0.82	1.51
PC 35:2; [M-Ac-H]-@6.45	ME190595	0.80	1.23	0.72	0.59	1.40	0.69	1.01	1.04	0.93	1.59
PE 32:0; [M-H]-@6.66	ME190629	0.72	1.09	0.93	0.51	1.57	0.71	0.96	1.07	0.67	1.77
plasmenyl-PE 42:6; [M-H]-@7.69	ME190742	0.68	0.89	1.00	0.71	1.45	0.69	0.83	1.03	0.91	1.81
PG 40:6; [M-H]-@5.36	ME190677	0.39	0.79	1.30	0.80	1.74	0.43	0.78	0.97	0.91	1.87
PI 38:5; [M-H]-@5.37	ME190698	0.47	0.72	1.36	0.65	1.74	0.48	0.92	1.36	0.63	1.68
FFA(16:0)	ME190557	0.52	0.85	1.25	0.49	1.75	0.58	0.98	1.29	0.51	1.78
PI 36:4; [M-H]-@5.27	ME190695	0.67	0.76	1.37	0.44	1.76	0.65	0.87	1.29	0.44	1.76
PS 36:1; [M-H]-@6.47	ME190708	0.69	0.77	1.11	0.69	1.48	0.77	0.91	1.22	0.70	1.64
FFA(24:0)	ME190569	0.65	0.80	1.19	0.73	1.69	0.63	0.95	1.07	0.73	1.57
plasmenyl-PE 40:4; [M-H]-@7.57	ME190738	0.65	0.82	1.06	0.77	1.58	0.64	0.97	1.10	0.84	1.56
FFA(18:0)	ME190558	0.57	0.93	1.28	0.55	1.58	0.65	1.04	1.26	0.56	1.58
FFA(20:0)	ME190561	0.57	0.98	1.30	0.58	1.64	0.62	1.08	1.20	0.61	1.43
plasmenyl-PE 36:5; [M-H]-@6.26	ME190732	0.49	0.85	1.19	0.67	1.61	0.53	0.94	1.15	0.77	1.80
FFA(22:0)	ME190565	0.54	0.89	1.23	0.58	1.58	0.61	1.05	1.16	0.67	1.68
plasmenyl-PE 40:6; [M-H]-@7.14	ME190739	0.60	0.95	1.22	0.58	1.48	0.68	1.03	1.11	0.58	1.77
PE 38:1; [M-H]-@7.82	ME190639	0.80	0.70	0.94	0.51	1.41	0.84	0.82	1.00	0.64	2.34
plasmenyl-PE 38:2; [M-H]-@7.71	ME190734	0.70	0.89	0.91	0.47	1.46	1.12	0.95	0.88	0.57	2.04
CL 70:5; [M-2H](2-)@5.92	ME190548	0.65	1.16	0.77	0.30	1.87	0.61	0.83	1.23	0.30	2.28
PE 36:3; [M-H]-@6.49	ME190635	0.71	0.84	0.82	0.46	1.81	0.92	0.64	0.96	0.55	2.29
plasmenyl-PE 34:2; [M-H]-@6.63	ME190729	0.59	0.92	0.96	0.39	1.82	0.81	0.91	1.05	0.42	2.14
Unknown_795.5176_[M-H]-@5.59	ME190722	0.44	0.77	1.31	0.62	1.09	0.49	0.85	1.25	0.67	2.52
plasmenyl-PE 36:0; [M-H]-@8.03	ME190731	0.50	0.55	1.31	0.35	1.79	0.68	0.76	1.61	0.44	2.01
PE 34:3; [M-H]-@5.86	ME190631	0.36	1.12	1.07	0.33	1.83	0.49	1.22	1.26	0.35	1.97
PE 36:5; [M-H]-@5.88	ME190636	0.40	1.14	0.99	0.22	1.91	0.45	1.30	1.19	0.29	2.11
PG 36:3; [M-H]-@5.30	ME190663	0.39	0.97	1.30	0.37	1.77	0.45	1.11	1.16	0.46	2.02
PS 38:5; [M-H]-@5.52	ME190715	0.41	0.93	1.39	0.29	1.67	0.44	0.98	1.46	0.42	2.00
FFA(22:1)	ME190566	0.31	1.05	1.34	0.63	1.34	0.37	1.10	1.13	0.73	2.00
PG 38:2; [M-H]-@6.22	ME190668	0.47	1.09	1.25	0.35	1.32	0.61	1.14	1.17	0.41	2.18
FFA(20:2)	ME190563	0.33	0.82	1.60	0.49	1.59	0.40	0.85	1.27	0.56	2.09
FFA(20:4) Arachidonic acid	ME190564	0.22	0.79	1.55	0.62	1.62	0.29	0.83	1.50	0.72	1.85
FFA(20:1)	ME190562	0.16	0.92	1.47	0.39	1.64	0.21	1.03	1.36	0.45	2.38
Unknown_782.4972_[M-H]-@5.99	ME190721	0.47	0.86	1.36	0.34	1.58	0.39	0.88	1.20	0.34	2.59
PG 32:2; [M-H]-@4.68	ME190652	0.14	3.27	0.88	0.05	0.08	0.12	4.42	0.93	0.05	0.06
PG 33:2; [M-H]-@4.73	ME190654	0.22	3.26	1.01	0.08	0.03	0.19	4.18	0.87	0.06	0.09
PE 33:2; [M-H]-@5.98	ME190630	0.27	3.95	0.64	0.23	0.19	0.27	3.15	0.77	0.30	0.24
PG 36:5; [M-H]-@4.59	ME190665	0.36	3.58	0.79	0.39	0.17	0.35	3.14	0.60	0.42	0.19
CL 62:1; [M-2H](2-)@5.50	ME190544	0.66	3.33	0.74	0.24	0.40	0.65	2.49	0.77	0.29	0.44
CL 66:3; [M-2H](2-)@5.72	ME190545	0.35	3.27	0.56	0.15	0.50	0.41	3.14	0.95	0.16	0.52
PG 34:3; [M-H]-@4.67	ME190657	0.33	2.89	1.00	0.34	0.30	0.47	3.07	0.86	0.31	0.43
PC 36:5; [M-Ac-H]-@5.61	ME190601	0.79	1.56	0.69	1.50	0.31	0.90	1.35	0.67	1.85	0.37
PG 35:3; [M-H]-@5.00	ME190659	0.59	2.65	0.89	0.45	0.37	0.73	2.20	0.70	1.18	0.22
PG 36:6; [M-H]-@4.18	ME190666	0.95	2.22	0.68	0.84	0.29	1.24	1.83	0.91	0.80	0.23
PG 39:7; [M-H]-@4.83	ME190675	0.59	2.24	0.90	1.12	0.18	0.62	2.20	0.63	1.31	0.20
PC 30:1; [M-Ac-H]-@5.30	ME190583	1.03	2.17	0.58	0.98	0.16	0.99	1.84	0.55	1.48	0.21
PG 37:5; [M-H]-@4.91	ME190667	0.87	2.28	0.61	1.27	0.17	0.67	1.56	0.63	1.64	0.30
PG 31:0; [M-H]-@5.49	ME190649	1.94	1.80	1.00	0.34	0.24	1.66	1.67	0.83	0.36	0.17
PG 32:1; [M-H]-@5.12	ME190651	1.34	1.85	1.25	0.17	0.40	1.27	1.78	1.26	0.21	0.47
PC 31:1; [M-Ac-H]-@5.62	ME190585	0.43	2.06	0.79	0.44	1.30	0.54	1.66	0.83	0.86	1.11
PS 30:0; [M-H]-@5.05	ME190702	0.64	1.37	1.20	0.46	1.21	0.97	1.67	1.49	0.68	0.31
PG 33:1; [M-H]-@5.56	ME190653	0.67	1.89	1.33	0.28	0.84	0.62	1.90	1.45	0.33	0.69
PC 32:1; [M-Ac-H]-@5.95	ME190586	0.54	1.54	1.33	0.47	0.77	0.64	1.80	1.38	0.55	0.98
plasmenyl-PE 33:1; [M-H]-@6.82	ME190728	0.61	1.76	1.11	0.52	0.90	0.64	1.81	1.08	0.68	0.89
CL 70:1; [M-2H](2-)@5.98	ME190547	0.85	1.76	0.99	0.63	0.47	0.77	1.73	1.46	0.65	0.71
plasmenyl-PE 32:1; [M-H]-@6.50	ME190727	0.80	2.11	0.86	0.62	0.55	0.88	1.72	0.99	0.89	0.59
PG 35:2; [M-H]-@5.38	ME190658	0.34	2.80	1.44	0.28	0.29	0.41	2.33	1.49	0.31	0.32
PG 38:7; [M-H]-@4.45	ME190673	0.39	2.87	1.29	0.50	0.16	0.53	2.53	0.89	0.60	0.24
PC 29:1; [M-Ac-H]-@4.96	ME190581	0.88	1.91	1.31	0.57	0.25	0.56	2.43	1.28	0.44	0.37
PG 34:2; [M-H]-@5.17	ME190656	0.25	2.42	1.81	0.07	0.37	0.33	2.18	2.00	0.11	0.46
CL 68:1; [M-2H](2-)@6.18	ME190546	0.33	1.75	1.57	0.24	0.81	0.32	2.24	1.62	0.32	0.79
PS 32:1; [M-H]-@5.23	ME190704	0.47	2.05	1.61	0.28	0.53	0.39	2.10	1.71	0.40	0.47

Factors:

F1	genotype:rage knockout \| treatment:BSA
F2	genotype:rage knockout \| treatment:conditioned media with BSA
F3	genotype:rage knockout \| treatment:conditioned media with palm + oleate
F4	genotype:rage knockout \| treatment:none
F5	genotype:rage knockout \| treatment:palm + oleate
F6	genotype:wild type \| treatment:BSA
F7	genotype:wild type \| treatment:conditioned media with BSA
F8	genotype:wild type \| treatment:conditioned media with palm + oleate
F9	genotype:wild type \| treatment:none
F10	genotype:wild type \| treatment:palm + oleate

Data matrix